Latest Breaking News On - First in human phasei clinical - Page 1 : comparemela.com

Proprietary TAT Phospholipid Conjugate Demonstrates Potent Activity in Resistant Pancreatic Cancer Initiating IND-enabling Studies for First-in-Human Phase I Clinical Study FLORHAM PARK, N.J., Jan. .

United statesClaire lacagninaCellectar biosciencesJames carusoCellectar biosciences incGlobenewswire incExchange commissionBliss bio healthConjugate demonstrates potent activityResistant pancreaticFirst in human phasei clinicalPhospholipid drug conjugate